HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

NextEdge Admin

05 Nov 2024

2 min 16 sec

At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics will showcase its flagship DNBSEQ-T7™ sequencer’s advancements, highlighting a wider application range and growing market adoption. Over the past year, DNBSEQ-T7 has gained traction due to its flexibility in sequencing various modalities—from DNA/RNA to protein—at high resolution and reduced cost, aligning with industry trends toward multi-omics (bulk, single-cell, and spatial omics). This expansion supports human genetics research across applications, including DNBSEQ CompleteWGS, spatial transcriptomics, proteomics, and single-cell sequencing.

Visitors to Booth #745 can explore a range of product innovations and demos, including:

- DNBSEQ-G400RS FluoXpert: A multifunctional sequencer combining high-throughput sequencing with multiplex immunofluorescence, enabling spatial protein detection and integrated DNA/RNA and protein data analysis.
- DNBSEQ-G800: A benchtop sequencer offering Q40 accuracy with read lengths beyond 600 bp, delivering unmatched single-read capabilities for high-precision variant calling.
- DNBelab-D4 Digital Sample Preparation System: A portable, automated system for creating DNA Nanoballs (DNBs) from DNA/RNA samples in under 3.5 hours, optimized for high-speed library preparation.
- DNBSEQ-G99: A sequencer achieving Q40 quality with two flow cells, capable of delivering up to 96 Gb in 30 hours for PE300.

Additionally, Complete Genomics will feature spatial transcriptomics solutions through a U.S. distribution agreement with STOmics, offering high-resolution, species-agnostic multi-omics technology, and introduce CompleteWGS—a high-coverage, cost-effective whole genome sequencing solution powered by DNBSEQ technology.